FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2954699144> ?p ?o ?g. }

• W2954699144 endingPage "CT178" @default.
• W2954699144 startingPage "CT178" @default.
• W2954699144 abstract "Abstract Background: Treatments for 1L advanced, unresectable, or metastatic UC include platinum-based chemotherapy, immune checkpoint blockade, or clinical trial enrollment. Not all patients benefit from, or are eligible for, specific therapies due to comorbidities and performance status. There is an urgent need for biomarker-directed strategies to enable patient selection and improve outcomes. Currently the only clinically used molecular biomarker is programmed cell death ligand-1 (PD-L1) protein expression in tumor tissue. Although variably defined with different assays, higher PD-L1 expression generally correlates with increased response rates to immune checkpoint blockade. Improved understanding of the prevalence and potential prognostic role of PD-L1 testing can further enhance its clinical utility and guide novel clinical trial designs. Methods: This observational study will enroll 250 patients diagnosed with advanced UC either prior to or during 1L therapy, as initiated at the discretion of participating clinicians from 60 US community sites. The primary endpoint is prevalence (with exact [Clopper-Pearson] 95% CI) of PD-L1 high expression by VENTANA SP263 Assay on pretreatment tumor tissue (classified as PD-L1 high if ≥25% of tumor cells [TCs] exhibit staining; or if immune cells [IC] present &gt;1% and IC with staining ≥25%; or IC present =1% and IC with staining =100%). Secondary endpoints include the association of pretreatment PD-L1 expression with pretreatment tumor tissue mutational burden (tTMB), descriptions of treatment response and outcomes (objective response rate based on RECIST 1.1, progressive-free survival [PFS], and overall survival [OS]) and assessment of their correlations with PD-L1 expression. Exploratory endpoints include the association of pretreatment tumor tissue PD-L1 with pretreatment blood-based tumor mutational burden (bTMB), changes in circulating tumor DNA levels, the correlation between tTMB and bTMB values, and the association of those biomarkers with PFS and OS. Enrollment will take place over 24 months. Patients will be followed for up to 30 months after enrollment. With 250 patients, the 95% CI for 30%, 45%, and 60% observed prevalence of PD-L1 high expression are (24.4%, 36.1%), (38.9%, 51.2%), and (53.6%, 66.1%), respectively; the various secondary and exploratory analyses will be descriptive. Citation Format: Petros Grivas, Alicia K. Morgans, Yair Lotan, Jeffrey Gregg, Daniel Geynisman, Terence Friedlander, Piyush K. Agarwal, Marija Tesic-Schnell, Andrew Bernstein, Doris Makari, Joshua J. Meeks. Prevalence of PD-L1 expression in 1st-line (1L) locally advanced/unresectable or metastatic urothelial carcinoma (UC) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr CT178." @default.
• W2954699144 created "2019-07-12" @default.
• W2954699144 creator A5010551367 @default.
• W2954699144 creator A5024887383 @default.
• W2954699144 creator A5026717218 @default.
• W2954699144 creator A5033372450 @default.
• W2954699144 creator A5041923034 @default.
• W2954699144 creator A5048082779 @default.
• W2954699144 creator A5066520421 @default.
• W2954699144 creator A5070812529 @default.
• W2954699144 creator A5073577602 @default.
• W2954699144 creator A5079570071 @default.
• W2954699144 creator A5084627594 @default.
• W2954699144 date "2019-07-01" @default.
• W2954699144 modified "2023-09-27" @default.
• W2954699144 title "Abstract CT178: Prevalence of PD-L1 expression in 1st-line (1L) locally advanced/unresectable or metastatic urothelial carcinoma (UC)" @default.
• W2954699144 doi "https://doi.org/10.1158/1538-7445.am2019-ct178" @default.
• W2954699144 hasPublicationYear "2019" @default.
• W2954699144 type Work @default.
• W2954699144 sameAs 2954699144 @default.
• W2954699144 citedByCount "0" @default.
• W2954699144 crossrefType "journal-article" @default.
• W2954699144 hasAuthorship W2954699144A5010551367 @default.
• W2954699144 hasAuthorship W2954699144A5024887383 @default.
• W2954699144 hasAuthorship W2954699144A5026717218 @default.
• W2954699144 hasAuthorship W2954699144A5033372450 @default.
• W2954699144 hasAuthorship W2954699144A5041923034 @default.
• W2954699144 hasAuthorship W2954699144A5048082779 @default.
• W2954699144 hasAuthorship W2954699144A5066520421 @default.
• W2954699144 hasAuthorship W2954699144A5070812529 @default.
• W2954699144 hasAuthorship W2954699144A5073577602 @default.
• W2954699144 hasAuthorship W2954699144A5079570071 @default.
• W2954699144 hasAuthorship W2954699144A5084627594 @default.
• W2954699144 hasConcept C121608353 @default.
• W2954699144 hasConcept C126322002 @default.
• W2954699144 hasConcept C141341695 @default.
• W2954699144 hasConcept C143998085 @default.
• W2954699144 hasConcept C170493617 @default.
• W2954699144 hasConcept C185592680 @default.
• W2954699144 hasConcept C203092338 @default.
• W2954699144 hasConcept C2776694085 @default.
• W2954699144 hasConcept C2777701055 @default.
• W2954699144 hasConcept C2778468042 @default.
• W2954699144 hasConcept C2779984678 @default.
• W2954699144 hasConcept C2780352672 @default.
• W2954699144 hasConcept C2780739268 @default.
• W2954699144 hasConcept C2780851360 @default.
• W2954699144 hasConcept C2781197716 @default.
• W2954699144 hasConcept C2911057145 @default.
• W2954699144 hasConcept C3019882237 @default.
• W2954699144 hasConcept C31760486 @default.
• W2954699144 hasConcept C535046627 @default.
• W2954699144 hasConcept C55493867 @default.
• W2954699144 hasConcept C71924100 @default.
• W2954699144 hasConceptScore W2954699144C121608353 @default.
• W2954699144 hasConceptScore W2954699144C126322002 @default.
• W2954699144 hasConceptScore W2954699144C141341695 @default.
• W2954699144 hasConceptScore W2954699144C143998085 @default.
• W2954699144 hasConceptScore W2954699144C170493617 @default.
• W2954699144 hasConceptScore W2954699144C185592680 @default.
• W2954699144 hasConceptScore W2954699144C203092338 @default.
• W2954699144 hasConceptScore W2954699144C2776694085 @default.
• W2954699144 hasConceptScore W2954699144C2777701055 @default.
• W2954699144 hasConceptScore W2954699144C2778468042 @default.
• W2954699144 hasConceptScore W2954699144C2779984678 @default.
• W2954699144 hasConceptScore W2954699144C2780352672 @default.
• W2954699144 hasConceptScore W2954699144C2780739268 @default.
• W2954699144 hasConceptScore W2954699144C2780851360 @default.
• W2954699144 hasConceptScore W2954699144C2781197716 @default.
• W2954699144 hasConceptScore W2954699144C2911057145 @default.
• W2954699144 hasConceptScore W2954699144C3019882237 @default.
• W2954699144 hasConceptScore W2954699144C31760486 @default.
• W2954699144 hasConceptScore W2954699144C535046627 @default.
• W2954699144 hasConceptScore W2954699144C55493867 @default.
• W2954699144 hasConceptScore W2954699144C71924100 @default.
• W2954699144 hasIssue "13_Supplement" @default.
• W2954699144 hasLocation W29546991441 @default.
• W2954699144 hasOpenAccess W2954699144 @default.
• W2954699144 hasPrimaryLocation W29546991441 @default.
• W2954699144 hasRelatedWork W2097545995 @default.
• W2954699144 hasRelatedWork W2101021708 @default.
• W2954699144 hasRelatedWork W2883599399 @default.
• W2954699144 hasRelatedWork W2954699144 @default.
• W2954699144 hasRelatedWork W3034884095 @default.
• W2954699144 hasRelatedWork W3089163820 @default.
• W2954699144 hasRelatedWork W4206284710 @default.
• W2954699144 hasRelatedWork W4285492859 @default.
• W2954699144 hasRelatedWork W4308189788 @default.
• W2954699144 hasRelatedWork W4361946883 @default.
• W2954699144 hasVolume "79" @default.
• W2954699144 isParatext "false" @default.
• W2954699144 isRetracted "false" @default.
• W2954699144 magId "2954699144" @default.
• W2954699144 workType "article" @default.